| Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML JE Maxson, J Gotlib, DA Pollyea, AG Fleischman, A Agarwal, CA Eide, ... New England Journal of Medicine 368 (19), 1781-1790, 2013 | 616 | 2013 |
| CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia A Pardanani, TL Lasho, RR Laborde, M Elliott, CA Hanson, RA Knudson, ... Leukemia 27 (9), 1870-1873, 2013 | 279 | 2013 |
| The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment J Gotlib, JE Maxson, TI George, JW Tyner Blood, The Journal of the American Society of Hematology 122 (10), 1707-1711, 2013 | 201 | 2013 |
| The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition AG Fleischman, JE Maxson, SB Luty, A Agarwal, LR Royer, ML Abel, ... Blood, The Journal of the American Society of Hematology 122 (22), 3628-3631, 2013 | 125 | 2013 |
| Cancer‐and endotoxin‐induced cachexia require intact glucocorticoid signaling in skeletal muscle TP Braun, AJ Grossberg, SM Krasnow, PR Levasseur, M Szumowski, ... The FASEB Journal 27 (9), 3572-3582, 2013 | 106 | 2013 |
| Genomics of chronic neutrophilic leukemia JE Maxson, JW Tyner Blood, The Journal of the American Society of Hematology 129 (6), 715-722, 2017 | 90 | 2017 |
| Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia KHT Dao, J Gotlib, MMN Deininger, ST Oh, JE Cortes, RH Collins, ... Journal of Clinical Oncology 38 (10), 1006-1018, 2020 | 87 | 2020 |
| Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia KHT Dao, MB Solti, JE Maxson, EF Winton, RD Press, BJ Druker, ... Leukemia research reports 3 (2), 67-69, 2014 | 85 | 2014 |
| Matriptase-2-and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression JE Maxson, J Chen, CA Enns, AS Zhang Journal of Biological Chemistry 285 (50), 39021-39028, 2010 | 84 | 2010 |
| Genomic landscape of neutrophilic leukemias of ambiguous diagnosis H Zhang, B Wilmot, D Bottomly, KHT Dao, E Stevens, CA Eide, V Khanna, ... Blood, The Journal of the American Society of Hematology 134 (11), 867-879, 2019 | 73 | 2019 |
| Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor … JE Maxson, SB Luty, JD MacManiman, ML Abel, BJ Druker, JW Tyner Journal of Biological Chemistry 289 (9), 5820-5827, 2014 | 64 | 2014 |
| CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML JE Maxson, RE Ries, YC Wang, RB Gerbing, EA Kolb, SL Thompson, ... Blood, The Journal of the American Society of Hematology 127 (24), 3094-3098, 2016 | 58 | 2016 |
| The colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I JE Maxson, SB Luty, JD MacManiman, JC Paik, J Gotlib, P Greenberg, ... Clinical Cancer Research 22 (3), 757-764, 2016 | 45 | 2016 |
| Processing of hemojuvelin requires retrograde trafficking to the Golgi in HepG2 cells JE Maxson, CA Enns, AS Zhang Blood, The Journal of the American Society of Hematology 113 (8), 1786-1793, 2009 | 43 | 2009 |
| Neogenin facilitates the induction of hepcidin expression by hemojuvelin in the liver N Zhao, JE Maxson, RH Zhang, M Wahedi, CA Enns, AS Zhang Journal of Biological Chemistry 291 (23), 12322-12335, 2016 | 38 | 2016 |
| The cell giveth and the cell taketh away: an overview of Notch pathway activation by endocytic trafficking of ligands and receptors EB Pratt, JS Wentzell, JE Maxson, L Courter, D Hazelett, JL Christian Acta histochemica 113 (3), 248-255, 2011 | 34 | 2011 |
| Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia TP Braun, C Coblentz, BM Smith, DJ Coleman, Z Schonrock, SA Carratt, ... Proceedings of the National Academy of Sciences 117 (24), 13670-13679, 2020 | 28 | 2020 |
| Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia TP Braun, M Okhovat, C Coblentz, SA Carratt, A Foley, Z Schonrock, ... Nature communications 10 (1), 1-15, 2019 | 27 | 2019 |
| Gain-of-function mutations in granulocyte colony–stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation H Zhang, C Coblentz, K Watanabe-Smith, S Means, J Means, JE Maxson, ... Journal of Biological Chemistry 293 (19), 7387-7396, 2018 | 27 | 2018 |
| Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia C Jenkins, SB Luty, JE Maxson, CA Eide, ML Abel, C Togiai, ER Nemecek, ... Science signaling 11 (539), 2018 | 26 | 2018 |
